Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CMA1 | P23946 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3435840 | 0.85 | KIF11 (0.46) | KIF11ACHEMAPK1CNR1CNR2 | |
| SCHEMBL15045357 | 0.83 | CNR1 (0.47) | ACHEMAPK1CNR1CNR2ALDH1A1 | |
| SCHEMBL21381766 | 0.83 | KIF11 (0.45) | KIF11ACHECNR1CNR2CES2 | |
| SCHEMBL1479166 | 0.83 | TAAR1 (0.53) | KIF11ACHECA1CA2CA7 | |
| SCHEMBL9094904 | 0.83 | KIF11 (0.45) | KIF11ACHEMAPK1TSHRCES2 | |
| SCHEMBL8411112 | 0.83 | KIF11 (0.45) | KIF11ACHECNR1CNR2CES2 | |
| SCHEMBL1416801 | 0.82 | RXRA (0.42) | ALDH1A1MAPTHTTSMN1; SMN2 | |
| SCHEMBL5644608 | 0.81 | CNR1 (0.52) | KIF11ACHECNR1CNR2CES2 | |
| Hydrochloric Acid SCHEMBL8508345 | 0.81 | TAAR1 (0.52) | KIF11ACHECA1CA2CA7 | |
| SCHEMBL2005286 | 0.81 | KIF11 (0.44) | KIF11ACHEMAPK1TSHRCES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2718285-B1 | HYDANTOIN DERIVATIVES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LTD (GB) | 2016-03-16 | — | — | EP | disclosed |
| EP-2718285-B1 | HYDANTOIN DERIVATIVES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LTD (GB) | 2016-03-16 | — | — | EP | disclosed |
| US-9193704-B2 | Hydantoin derivatives as KV3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2015-11-24 | — | — | US | disclosed |
| US-9193704-B2 | Hydantoin derivatives as KV3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2015-11-24 | — | — | US | disclosed |
| US-9193704-B2 | Hydantoin derivatives as KV3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2015-11-24 | — | — | US | disclosed |
| US-20140107139-A1 | HYDANTOIN DERIVATIVES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2014-04-17 | — | — | US | disclosed |
| US-20140107139-A1 | HYDANTOIN DERIVATIVES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2014-04-17 | — | — | US | disclosed |
| US-20140107139-A1 | HYDANTOIN DERIVATIVES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2014-04-17 | — | — | US | disclosed |
| EP-2718285-A1 | HYDANTOIN DERIVATES AS KV3 INHIBITORS | Autifony Therapeutics Limited (GB) | 2014-04-16 | — | — | EP | disclosed |
| WO-2012168710-A1 | HYDANTOIN DERIVATES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012168710-A1 | HYDANTOIN DERIVATES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2012-12-13 | — | — | WO | disclosed |
| WO-1998007716-A2 | HETEROAROTINOIDS-ANTICANCER AGENTS WITH RECEPTOR SPECIFICITY AND TGASE ACTIVITY | THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY (US) | 1998-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107139-A1 | HYDANTOIN DERIVATIVES AS KV3 INHIBITORS | KCNA3, KCND3, KCNN3 | KIF11 1785/4885ACHE 566/4885MAPK1 2183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.